OBJECTIVE: Investigate the efficacy of @entity36584 capsules (NAB) in reducing the frequency and intensity of nightmares in subjects with @entity1005 . @entity1 AND METHODS: Canadian male military personnel with @entity1005 , who despite standard treatment continued to experience @entity130 -related nightmares, received double-blind treatment with 0.5mg NAB or placebo ( @entity20333 ), and then titrated to the effective dose (nightmare suppression) or reaching a maximum of 3.0mg. Subjects were followed for 7 weeks and then, following a 2-week washout period, were titrated with the other study treatment and followed for an additional 7 weeks. The modified intent-to-treat (mITT) population, which included all treated subjects that met inclusion/exclusion criteria, was analyzed. RESULTS: Ten subjects were included in the mITT population. The mean reduction in nightmares as measured by the CAPS Recurring and Distressing Dream scores were -3.6  2.4 and -1.0  2.1 in the NAB and @entity20333 groups, respectively (p=0.03). Mean global improvement as measured by the Clinical Global Impression of Change (CGI-C) was 1.9  1.1 (i.e. much improved) and 3.2  1.2 (i.e. minimally improved) in the NAB and @entity20333 groups, respectively (p=0.05) Five out of 10 (50%) were much improved on NAB versus 1 out of 9 (11%) on @entity20333 . Results for the General Well Being Questionnaire (WBQ) were 20.8  22 and -0.4  20.6 in the NAB and @entity20333 groups, respectively (p=0.04). The proportion of subjects who experienced a treatment-related occurrence of adverse events was 50% in the NBO group and 60% in the @entity20333 group. No event was severe nor resulted in a drop-out. This study is registered with Health Canada. CONCLUSION: In this small sample NAB provided significant relief for military personnel with @entity1005 , indicating that it shows promise as a clinically-relevant treatment for @entity1 with nightmares and a history of non-response to traditional therapies. These findings need to be replicated in a larger cohort. There is a need for further exploration of the effect of @entity36584 on other symptoms of @entity1005 such as re-experiencing, hyper @entity2844 and @entity22 .

The efficacy of @entity36584 , a synthetic cannabinoid, in the treatment of XXXX -associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity2844 :: ('MESH:D000405', 'Disease') :: ['vigilance'] @entity1005 :: ('MESH:D013313', 'Disease') :: ['PTSD'] @entity20333 :: ('CHEBI:61603', 'Chemical') :: ['PBO'] @entity36584 :: ('MESH:C011941', 'Chemical') :: ['nabilone'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma'] @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']
@entity1005 :: (MESH:D013313,Disease) :: ['PTSD']
